Where will advances in remote cardiac and kidney monitoring lead?

Remote biometric monitoring technology company Biotricity recently announced securing National Institutes of Health funding from the National Heart, Blood and Lung Institute with plans to launch a study of its Bioflux-AI technology.

Bioflux-AI combines an FDA-approved, high-precision, small mobile cardiac telemetry device with AI-driven algorithms specifically trained for the prediction of stroke in stage 4 and stage 5 chronic kidney disease…